文献速递消化内镜消化道肿瘤与早癌

一种可经针注射的电外科刀用于内镜黏膜下剥离术的多中心回顾性研究

A multicenter, retrospective study of a through-the-needle injection-capable electrosurgical knife for endoscopic submucosal dissection.
PubMed 文献 · Gastrointest Endosc · 2024-06-13

在美国6家学术中心开展的单臂回顾性研究,评估一种新型可经针注射电外科刀用于上、下消化道内镜黏膜下剥离术(ESD)的安全性和有效性。共回顾579例患者581处病变,成功ESD率为82.1%,治愈性切除率为76.2%,相关严重不良事件发生率为2.6%。

要点

  • 581处病变成功ESD率为82.1%,治愈性切除率为76.2%。
  • 伴黏膜下纤维化者成功ESD率低于无纤维化者(73.6% vs 87.0%,P < .001)。
  • 相关严重不良事件见于15例(2.6%)患者,包括迟发出血1.9%、穿孔0.5%、息肉切除后综合征0.2%。

核心结论

  • 新型可经针注射ESD刀在美国各中心显示出良好的成功率和优异的安全性。

研究设计与样本

  • 单臂回顾性研究,回顾性收集美国6家学术中心连续使用该新型ESD刀的病例,共579例患者581处病变(上消化道187处,占32.2%;下消化道394处,占67.8%)。

主要发现

  • 581处病变中477处(82.1%)实现成功ESD;伴黏膜下纤维化者成功ESD率为73.6%,无纤维化者为87.0%(P < .001)。
  • 有既往治疗者与无既往治疗者的成功ESD率分别为81.7%与82.3%(P = .848)。
  • 443处(76.2%)病变符合治愈性切除标准;中位ESD时间为1.0小时(范围0.1-4.5小时),中位剥离速度为17.1 cm2/h(四分位距5.3-29.8)。
  • 相关严重不良事件见于15例(2.6%)患者,包括迟发出血(1.9%)、穿孔(0.5%)和息肉切除后综合征(0.2%)。

关键数值与推荐

  • 原文未报告

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) is a technically challenging resection technique for en bloc removal of dysplastic and early cancerous GI lesions. We conducted a single-arm retrospective study evaluating the safety and efficacy of a new through-the-needle injection-capable electrosurgical knife used in upper and lower ESD procedures performed at 6 U.S. academic centers. METHODS: Data were retrospectively collected on consecutive cases in which the new ESD knife was used. The primary efficacy endpoint was successful ESD (en bloc resection with negative margins). Secondary efficacy endpoints included en bloc resection rate, curative resection rate, median ESD time, and median dissection speed. The safety endpoint was device- or procedure-related serious adverse events. RESULTS: ESD procedures of 581 lesions in 579 patients were reviewed, including 187 (32.2%) upper GI and 394 (67.8%) lower GI lesions. Prior treatment was reported in 283 (48.9%) patients. Successful ESD was achieved in 477 (82.1% of 581) lesions-lower for patients with versus without submucosal fibrosis (73.6% vs 87.0%, respectively; P < .001) but similar for those with versus without previous treatment (81.7% vs 82.3%, respectively; P = .848). A total of 443 (76.2% of 581) lesions met criteria for curative resection. Median ESD time was 1.0 (range, 0.1-4.5) hour. Median dissection speed was 17.1 (interquartile range, 5.3-29.8) cm2/h. Related serious adverse events were reported in 15 (2.6%) patients, including delayed hemorrhage (1.9%), perforation (0.5%), or postpolypectomy syndrome (0.2%). CONCLUSION: A newly developed through-the-needle injection-capable ESD knife showed a good success rate and excellent safety at U.S. CENTERS: (Clinical trial registration number: NCT04580940.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Aihara H, Othman MO, Jawaid SA, et al. A multicenter, retrospective study of a through-the-needle injection-capable electrosurgical knife for endoscopic submucosal dissection. Gastrointest Endosc. 2024. PMID: 38879045. doi:10.1016/j.gie.2024.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。